BIOMAT Database Logo BIOMAT Database Logo

Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. 2002

Masoud Nahavandi, and Fatemeh Tavakkoli, and Melville Q Wyche, and Elliott Perlin, and William P Winter, and Oswaldo Castro
Department of Anaesthesiology, and Center For Sickle Cell Disease, College of Medicine, Howard University, Washington, DC 20060, USA. mnahavandi@Howard.edu

Recent studies suggest that nitric oxide (NO) may partly be responsible for the beneficial effect of hydroxyurea (HU) in sickle cell disease (SCD) patients. NO stimulates cyclic guanosine monophosphate (cGMP) production, which mediates vasodilatation. We investigated the association between NO, cGMP and fetal haemoglobin (HbF) levels after HU administration. Our data showed that chronic HU significantly increased NO, cGMP, and HbF levels in SCD. Recently it was shown that HbF production was stimulated by cGMP-dependent protein kinase. Our results suggest that NO stimulates cGMP production, which then activates a protein kinase and increases the production of HbF.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D005260 Female Females
D005319 Fetal Hemoglobin The major component of hemoglobin in the fetus. This HEMOGLOBIN has two alpha and two gamma polypeptide subunits in comparison to normal adult hemoglobin, which has two alpha and two beta polypeptide subunits. Fetal hemoglobin concentrations can be elevated (usually above 0.5%) in children and adults affected by LEUKEMIA and several types of ANEMIA. Hemoglobin F,Hemoglobin, Fetal
D006152 Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) Guanosine Cyclic 3',5'-Monophosphate,Guanosine Cyclic 3,5 Monophosphate,Guanosine Cyclic Monophosphate,Guanosine Cyclic-3',5'-Monophosphate,3',5'-Monophosphate, Guanosine Cyclic,Cyclic 3',5'-Monophosphate, Guanosine,Cyclic Monophosphate, Guanosine,Cyclic-3',5'-Monophosphate, Guanosine,GMP, Cyclic,Guanosine Cyclic 3',5' Monophosphate,Monophosphate, Guanosine Cyclic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000755 Anemia, Sickle Cell A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S. Hemoglobin S Disease,HbS Disease,Sickle Cell Anemia,Sickle Cell Disease,Sickle Cell Disorders,Sickling Disorder Due to Hemoglobin S,Anemias, Sickle Cell,Cell Disease, Sickle,Cell Diseases, Sickle,Cell Disorder, Sickle,Cell Disorders, Sickle,Disease, Hemoglobin S,Hemoglobin S Diseases,Sickle Cell Anemias,Sickle Cell Diseases,Sickle Cell Disorder

Related Publications

Masoud Nahavandi, and Fatemeh Tavakkoli, and Melville Q Wyche, and Elliott Perlin, and William P Winter, and Oswaldo Castro
Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease.
February 2002, British journal of haematology,
Masoud Nahavandi, and Fatemeh Tavakkoli, and Melville Q Wyche, and Elliott Perlin, and William P Winter, and Oswaldo Castro
Nitric oxide and cyclic GMP signaling.
January 1996, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Masoud Nahavandi, and Fatemeh Tavakkoli, and Melville Q Wyche, and Elliott Perlin, and William P Winter, and Oswaldo Castro
Nitric oxide-cyclic GMP signaling in stem cell differentiation.
December 2011, Free radical biology & medicine,
Masoud Nahavandi, and Fatemeh Tavakkoli, and Melville Q Wyche, and Elliott Perlin, and William P Winter, and Oswaldo Castro
Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice.
May 2021, American journal of physiology. Regulatory, integrative and comparative physiology,
Masoud Nahavandi, and Fatemeh Tavakkoli, and Melville Q Wyche, and Elliott Perlin, and William P Winter, and Oswaldo Castro
Nitric oxide and cyclic GMP functions in bone.
June 2018, Nitric oxide : biology and chemistry,
Masoud Nahavandi, and Fatemeh Tavakkoli, and Melville Q Wyche, and Elliott Perlin, and William P Winter, and Oswaldo Castro
Nitric oxide/cyclic GMP-mediated signal transduction.
September 1994, Annals of the New York Academy of Sciences,
Masoud Nahavandi, and Fatemeh Tavakkoli, and Melville Q Wyche, and Elliott Perlin, and William P Winter, and Oswaldo Castro
Nitric oxide-cyclic GMP signal transduction system.
January 1996, Methods in enzymology,
Masoud Nahavandi, and Fatemeh Tavakkoli, and Melville Q Wyche, and Elliott Perlin, and William P Winter, and Oswaldo Castro
Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease.
August 2003, Journal of pediatric hematology/oncology,
Masoud Nahavandi, and Fatemeh Tavakkoli, and Melville Q Wyche, and Elliott Perlin, and William P Winter, and Oswaldo Castro
Cellular signaling with nitric oxide and cyclic GMP.
November 1999, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
Masoud Nahavandi, and Fatemeh Tavakkoli, and Melville Q Wyche, and Elliott Perlin, and William P Winter, and Oswaldo Castro
Nitric oxide stimulates cyclic GMP in human thyrocytes.
April 1993, Journal of molecular endocrinology,
Copied contents to your clipboard!